The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for NHS use in England and Wales.
This treatment targets adults with HER2-negative, locally advanced or metastatic breast cancer who have germline BRCA1 or BRCA2 mutations, following chemotherapy.
Germline BRCA1 and BRCA2 mutations account for 5% to 10% of all breast cancers, with genetic testing being essential for optimal care.
Professor Andrew Tutt, Director of the Toby Robins Breast Cancer Now Research Centre, said: “Locally advanced or metastatic HER2-negative breast cancer remains a devastating diagnosis. For those with this form of breast cancer and inherited BRCA-mutations, the OlympiAD phase 3 trial demonstrated how olaparib can significantly delay cancer progression or death compared to standard chemotherapies.”…
